Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).

被引：0
|
作者：
Ramakrishnan, Karthik
Jain, Disha
Gandhi, Jyotika
Chirovsky, Diana Romana
Borse, Rebekah
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] CHEORS, N Wales, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18013
引用
收藏
页数：3
相关论文
共 50 条
  • [41] PembrolIzumab plus platinum and gemcitabine as first-line treatment of recurrent head and neck squamous cell carcinoma
    Ishak, W. Binti Wan
    Cheong, S.
    Nor, I. Muhamad
    Selvam, B.
    Ho, G.
    Tan, C.
    Wong, Y.
    Kue, P.
    Wai, A.
    Yahya, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1386 - S1386
  • [42] Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study
    Gui, L.
    Chen, X.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1609 - S1610
  • [43] Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Borcoman, Edith
    Marret, Gregoire
    Le Tourneau, Christophe
    CANCERS, 2021, 13 (11)
  • [44] Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma
    Weiss, Jared M.
    Bagley, Stephen
    Hwang, Wei-Ting
    Bauml, Joshua
    Olson, Juneko Grilley
    Cohen, Roger B.
    Hayes, David Neil
    Langer, Corey
    CANCER, 2016, 122 (15) : 2350 - 2355
  • [45] Sequential Treatment Use in Clinical Practice for US Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Zheng, D.
    Black, C. M.
    Hair, G. M.
    Bidadi, B.
    Lerman, N.
    Ai, L.
    Zion, A.
    Zou, L.
    Gao, W.
    Hanna, G. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E34
  • [46] Real-world time on treatment analysis of pembrolizumab treated recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC) patients stratified by ECOG PS in the United States.
    Black, Christopher Matthew
    Wang, Liya
    Ramakrishnan, Karthik
    Turzhitsky, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18007 - E18007
  • [47] Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Rischin, Danny
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash C.
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett Gordon Maxwell
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Zhang, Yayan
    Jin, Fan
    Gumuscu, Burak
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] COST-EFFECTIVENESS (CE) ANALYSES FOR FIRST-LINE (1L) TREATMENT OF ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (MUC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Braun, N.
    Auti, P.
    Arca, E.
    Teitsson, S.
    Broughton, E.
    May, J. R.
    Kurt, M.
    Alleman, C.
    VALUE IN HEALTH, 2022, 25 (01) : S44 - S44
  • [49] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios
    ORAL ONCOLOGY, 2024, 158
  • [50] Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
    Sun, L.
    Cohen, R.
    Colevas, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E35
12345